What Kind of HRT Is There? Types, Routes, and Regimens Explained

The fast answer: the four FDA types

Source: FDA menopausal hormone therapy categories and 2025–2026 labeling updates (FDA.gov; HHS.gov). FDA-approved and compounded options are kept separate throughout this guide.

Is this guide for you?

This is for you if:

• You keep seeing patches, pills, gels, creams, and progesterone described as different “types” and can’t tell them apart.
• You’re getting ready for a menopause or perimenopause appointment and want to walk in informed.
• You want to understand the options before you compare providers or pay for anything.

This isn’t enough on its own if:

• You have unexplained or postmenopausal bleeding.
• You’re pregnant or could be pregnant.
• You have a history — like blood clots, stroke, breast or uterine cancer, or liver disease — that can change whether hormone therapy is safe for you.
• You’re trying to start, stop, or change a prescription without a clinician. This page prepares you for that conversation. It doesn’t replace it.

Those situations need a licensed clinician, not a web page or a quiz. The Menopause Society and the FDA list pregnancy, unexplained bleeding, and certain clot, heart, and cancer histories among the things that require an individual medical review.

What we actually verified for this guide

What kind of HRT is there? The 5 decisions behind every plan

The FDA names four types of menopause hormone therapy, but a real prescription is defined by five separate decisions: where it works (whole-body or local), which hormones it contains (estrogen alone or estrogen plus a progestogen), how it’s delivered (pill, patch, gel, spray, or vaginal), how it’s scheduled (daily or part of the month), and whether it’s an FDA-approved product or a compounded one. These aren’t competing “types.” They’re five layers of the same choice.

Here’s why this matters. One site says there are “two types of HRT.” Another says “four.” A third lists seven patches, pills, and creams. None of them is wrong — they’re each describing a different layer. Once you see the layers, the confusion clears up.

We built this map — we call it the Five-Decision HRT Map— so you can place any prescription on it and understand what it is. Read across the row. That’s your plan.

The Five-Decision HRT Map is The HRT Index’s editorial framework, assembled from current FDA categories, product labels, and professional guidance. It organizes the options — it is not a clinical or diagnostic tool, and it doesn’t decide what’s right for you.

We’ll take these one at a time, in the order that actually helps you decide. Reach first, because it’s the biggest fork.

In a hurry? You can jump to “Which kind of HRT is right for you?” — but the sections in between are what make that part click.

What’s the difference between systemic and local HRT?

Systemic HRT is absorbed throughout your body and treats whole-body symptoms like hot flashes, night sweats, and disrupted sleep. Low-dose vaginal estrogen acts mostly where you place it — easing dryness, painful sex, and some urinary symptoms — with very little reaching your bloodstream, so on its own it generally does not treat hot flashes.

This is the first question a good clinician is quietly asking: what’s actually bothering you, and where?

When a systemic path usually comes up

If your main problems are whole-body — hot flashes, night sweats, waking up drenched, sleep that’s wrecked by them — that points toward systemic treatment (a pill, patch, gel, or spray that circulates). Systemic hormone therapy is FDA-approved for moderate-to-severe hot flashes and night sweats (the medical term is vasomotor symptoms), and it’s the most effective treatment available for them.

When a local vaginal path usually comes up

If your main problems are below the belt — vaginal dryness, burning, pain with sex, or recurrent urinary tract infections linked to menopause — that points toward low-dose vaginal estrogen. Doctors group these under genitourinary syndrome of menopause(GSM, the menopause-related changes to vaginal and urinary tissue). The dose is small and stays mostly local, which is why its risk conversation is different from systemic estrogen’s.

The trap that’s easy to miss: “vaginal” doesn’t mean “local”

Here’s a detail that trips up even careful readers. The word vaginal tells you where a product is placed — not whether it acts locally or on your whole body. Two vaginal rings prove it:

• Estring is a low-dose, local ring. It releases about 7.5 micrograms of estradiol a day into nearby tissue.
• Femring is a higher-dose, systemic ring. It treats whole-body symptoms like hot flashes.

Same body part. Completely different jobs. Always check the exact product, not just the form.

Can you use both?

Yes. Some women on systemic HRT still get vaginal symptoms and add a low-dose vaginal product for local relief. “Both” is a normal answer, not a mistake.

Want to go deeper on the local route? See our low-dose vaginal estrogen guide.

Do I need progesterone with estrogen?

If you’ve had a hysterectomy, estrogen alone is commonly used when hormone therapy is otherwise appropriate. If you still have a uterus and take systemic estrogen, you generally need lining protection too — because estrogen on its own can thicken the uterine lining over time, and a progestogen keeps that lining in check. This is one of the biggest reasons two women get different prescriptions.

Why the uterus changes the answer

Estrogen tells the lining of your uterus (the endometrium) to grow. With nothing to balance it, that growth can become unhealthy and raise the risk of uterine cancer. A progestogen (an umbrella word for progesterone and progesterone-like medicines) keeps the lining thin and protected. So:

• Uterus + systemic estrogen → you generally need an endometrial-protection plan — usually a progestogen, sometimes another FDA-approved option (more on that below).
• No uterus → estrogen alone is usually appropriate when hormone therapy is otherwise suitable. The lining-protection reason no longer applies. (Other safety questions still do.)

Low-dose vaginalestrogen is a different story — the dose is so small that it follows its own, separate discussion, and a progestogen usually isn’t added just for it. (Unexplained bleeding still always needs to be checked.)

Progesterone, progestin, progestogen — sorted in 15 seconds

• Progestogen — the umbrella term for this whole hormone family.
• Progesterone — one specific progestogen. The version that matches your body’s own is called micronized progesterone (FDA-approved as Prometrium, plus generics).
• Progestin — the common word for synthetic progesterone-like medicines, such as medroxyprogesterone (Provera) or norethindrone.

They all do the same core job — protecting the lining — but only when the right medicine, dose, and schedule are used, and they differ in side effects and parts of the risk picture. So the choice is worth a real conversation, not an assumption that they’re interchangeable.

Three ways the progestogen shows up

1. Two products — your estrogen (any route) plus a separate progestogen pill.
2. One combined product — estrogen and a progestogen together. Examples include Bijuva (an FDA-approved oral capsule of estradiol and progesterone for moderate-to-severe hot flashes in postmenopausal women with a uterus), plus oral combinations like Activella and Angeliq, and combination patches like Combipatch.
3. A hormonal IUD — some clinicians use a levonorgestrel IUD (like Mirena) to protect the lining. Note: for menopause, that’s an off-label use, not its FDA-approved purpose.

The “no separate progestogen” option

An FDA-approved option that protects the lining without a traditional progestogen is Duavee, which pairs conjugated estrogens with bazedoxifene (a selective estrogen receptor modulator, or SERM). It also helps prevent osteoporosis. Don’t read it as a universal “skip progesterone” hack — it’s a specific product with its own label and trade-offs. Confirm current availability before counting on it.

After a hysterectomy

No uterus usually means no need for the lining-protection progestogen. But “no progestogen” doesn’t mean “no other considerations” — your history still shapes the safest plan.

You’ve got the categories. The next step is mapping them to you.

Whether you need lining protection, whether your symptoms point systemic or local — that depends on your specific situation. That’s exactly what Find My HRT Path is built to sort out, privately, before you book anything.

How do HRT pills, patches, gels, sprays, and vaginal products compare?

The route is simply how the medicine gets in — and it doesn’t tell you which hormones are inside. Pills, patches, gels, sprays, and vaginal products differ in convenience, skin tolerance, daily routine, and part of the safety picture, so no single route is best for everyone. One key fact: estrogen taken as a pill passes through the liver first, which is linked to higher blood-clot risk, while skin routes largely skip that step.

Here’s the full route picture, with the question to ask about each.

Product availability can change. Confirm your exact product’s current status and label with your pharmacist. Examples current as of June 2026.

Why “transdermal” doesn’t mean “local”

A patch, gel, or spray is applied to one spot on your skin — but the estrogen still travels through your whole body. Transdermal (through the skin) describes how it gets in, not where it acts. All three are systemic.

The honest version of “skin routes skip the liver”

• Transdermal estrogen (patch, gel, spray) avoids the first pass through the liver that oral estrogen takes.
• Low-dose vaginal estrogen puts very little into the bloodstream at all.
• Femring is a systemic vaginal ring — don’t group it with the low-dose local vaginal products.

The clot question, stated carefully

For some women, skin routes have a friendlier clot-risk profile than pills, because pills pass through the liver first. The Menopause Society notes blood-clot risk rises with oral hormones and may be lowerwith transdermal estrogen; ACOG similarly notes oral estrogen can have a clot-promoting effect while transdermal has little or none. That’s a real consideration to raise with your clinician — not a promise that any skin product is risk-free or right for you.

What’s the difference between continuous and cyclic HRT?

If your plan includes a progestogen, there are two common schedules. Continuous-combined means you take estrogen and the progestogen together every day. Cyclic (also called sequential) means you take estrogen continuously and add the progestogen for only part of each month. The right one depends on your menopause stage and the product — and it changes the bleeding you should expect.

Schedule is about timing, not ingredients or route. A “continuous” plan can be a pill or a patch.

• Continuous-combined — both hormones, every day. Often used once you’re past menopause, usually aiming for no monthly bleed (some spotting in the first months is common).
• Cyclic / sequential — estrogen every day, progestogen for part of the cycle. This usually produces a scheduled monthly bleed, and it’s often used closer to the menopause transition.

One honest note about bleeding: there’s no single timetable for what’s “normal,” because it depends on your regimen and stage. Continuous-combined therapy can cause spotting early on; cyclic therapy is designedto produce a scheduled bleed. What should always be reported is bleeding that’s new, heavy, persistent, or outside the pattern your regimen is expected to produce.

This is also why the schedule isn’t a do-it-yourself choice. It hinges on whether you’re still having periods, whether you have a uterus, your exact product, your dose, and your bleeding history.

Is bioidentical HRT the same as compounded HRT?

No. “Bioidentical” describes a hormone’s chemical structure — it means the molecule matches the one your body makes — and it is not an FDA approval category. “Compounded” describes how a product is made and regulated. Many FDA-approved products are bioidentical (estradiol, micronized progesterone, and the combined capsule Bijuva). Compounded products are custom-made and are not FDA-approved, so they should never be presented as safer, more natural, or equal to FDA-approved medicine.

This is where marketing has done real damage, so let’s separate the words from the facts.

What “bioidentical” actually tells you

It tells you the chemistry matches your body’s hormones. That’s it. It is notan FDA approval level, and it does not tell you whether a product is FDA-approved, who made it, whether the dose is consistent, or whether it was compounded. Plenty of standard, FDA-approved products meet the everyday definition of “bioidentical.”

The term-by-term map

What compounded HRT actually is — and when it has a role

Compounded hormones come in two forms: a licensed pharmacist or physician can mix a custom preparation for one specific patient (known as 503A compounding), or an FDA-registered “outsourcing facility” can prepare batches (503B). Either way, the finished compounded product is not FDA-approved— the FDA does not review it for safety, effectiveness, or quality before it’s marketed.

That doesn’t make compounding always wrong. Major bodies — ACOG, The Menopause Society, the Endocrine Society — advise against using compounded hormones routinelywhen an FDA-approved option exists, and generally reserve them for specific cases, such as an allergy to an ingredient in an approved product. If a provider suggests compounded, it’s fair to ask exactly why an FDA-approved option won’t work for you.

Two quick myth-busters

• “Natural” and “plant-derived” are not safety or approval categories. Where a hormone starts (yam, soy, etc.) tells you nothing about whether the finished product is safe, effective, or regulated — and many FDA-approved hormones start from plant sources too.
• Estriol. You may see compounded formulas built around estriol, a form of estrogen. The FDA states there are no FDA-approved drugs that contain estriol, and that it has no evidence estriol-containing drugs are a safer form of estrogen.

For the full picture, see our 2026 FDA labeling-change guide.

Want to make sure you’re being offered an FDA-approved option — or understand why compounding is on the table?

That’s exactly the kind of thing worth sorting before you pay for a consult.

What about testosterone, pellets, and injections?

These don’t sit beside the four main HRT types as equal starting choices. Testosterone may be discussed in specific cases, but there is no FDA-approved testosterone product for women in the United States, so it’s used off-label — and it’s a controlled substance that requires a prescription. Pellets and injections are not the route major guidelines recommend, and each needs careful, product-by-product discussion.

It’s easy to see “testosterone for women” everywhere right now and assume it’s a standard fifth type of HRT. It isn’t. Here’s the careful version.

Testosterone for women in the US

There is no FDA-approved testosterone product for women in the US. That makes every form — creams, gels, injections, pellets — off-label. Testosterone is also a Schedule III controlled substance under federal law, which means it requires a DEA-registered prescriber, controlled-substance prescribing rules, and cannot be called in by a telehealth provider who isn’t properly registered.

The clearest supported use is for hypoactive sexual desire disorder(HSDD) — diagnosed low sexual desire — after menopause, where evidence from research and international clinical guidelines (including from ISSWSH) supports its use in carefully selected patients. It’s not a standard part of menopause treatment, and it’s not right for most women who are managing vasomotor symptoms or GSM.

Hormone pellets

Pellets are small, rice-sized implants inserted under the skin — typically every three to six months. They usually contain testosterone, sometimes estradiol. Major professional organizations, including the British Menopause Society and The Menopause Society, do not recommend pellets as a standard delivery route, in part because dosing is unpredictable and corrections require another procedure. Any provider recommending pellets as the first or obvious choice warrants careful questioning about what FDA-approved alternatives were considered.

Injections

Estrogen and testosterone can both be given by injection. Injections are not a standard route in US menopause management guidelines, and hormone levels can fluctuate considerably between doses. They remain available and used, but they’re not the place to start without a specific reason.

Which kind of HRT is right for you?

The right HRT type depends on your symptoms, your uterus status, your risk history, your route preferences, and your life. No single type is universally best. Here’s how the most common situations tend to map — so you can walk into your appointment with the right questions already in hand.

This table shows common starting points, not prescriptions. Your clinician’s decision may differ based on your history, preferences, and available products. Always discuss with a licensed clinician before starting, stopping, or changing any medication.

Which type of HRT is the safest?

No single type or route is universally the safest for every woman. The safety of a hormone plan depends on the specific estrogen, progestogen, dose, route, and schedule — and on your individual history. What the research does show is that the overall risks of HRT have been substantially revised since 2002, and that for healthy women under 60 or within ten years of menopause, the benefits of treating moderate-to-severe symptoms generally outweigh the risks.

This matters because the 2002 Women’s Health Initiative (WHI) study created lasting fear of HRT, including fear based on results that applied to older women (average age 63) and a specific type of oral combined HRT. That fear has since been substantially revised. In November 2025, the FDA acted on updated evidence by initiating removal of “black box” warnings from most menopausal hormone therapy products, and in February 2026, the FDA finalized labeling changes that clarify the benefit/risk picture — removing the blanket cardiovascular and cancer warnings that had been on the label since the WHI.

What changed (and what didn’t)

• Revised: The blanket warnings about cardiovascular risk, breast cancer risk, and stroke have been updated to reflect more nuanced, age- and timing-specific evidence.
• Revised: HRT is no longer uniformly described as contraindicated for women seeking menopause treatment. Timing matters: starting within ten years of menopause or before age 60 appears to carry a more favorable risk profile.
• Not changed: Individual risk factors still matter enormously — your history with clots, heart disease, or hormone-sensitive cancers shapes whether any HRT is appropriate, and which type and route.
• Not changed: Endometrial protection is still required for women with a uterus who use systemic estrogen.

For a full account of the 2025–2026 FDA labeling changes, see our 2026 FDA labeling-change guide. For the broader risk-benefit picture, see our HRT benefits and risks guide.

Why is HRT terminology so confusing?

Because the words describe different things that all overlap. “Type,” “route,” “schedule,” and “regulatory status” each answer a separate question, and most explainers mix them together — so “patch,” “combined,” and “bioidentical” end up sounding like rival choices when they’re really describing one plan from different angles.

If the vocabulary feels like a wall, you’re in good company. These are the kinds of questions women search and post all the time:

• “I know I need it — I just don’t know specifically what I need.”
• “Why would I want a patch instead of a pill or a gel?”
• “Is that for safety reasons, or just preference?”

(These are representative of the questions women commonly ask — shared to show the confusion is normal, not as medical advice or product reviews. The answers in this guide come from the FDA and major medical organizations.)

The fact that this is confusing isn’t a you problem. The vocabulary genuinely overlaps. That’s the whole reason we built the five-decision map — so the words finally line up.

What should I verify before starting or changing HRT?

Before you pay for a consult or fill a prescription, get clear on what symptom the treatment targets, whether it’s systemic or local, which hormones it contains, whether you need lining protection, the exact route and schedule, its FDA-or-compounded status, and how follow-up works. The goal isn’t to self-prescribe — it’s to make sure no important question gets skipped.

We made you a checklist. Print it, screenshot it, bring it.

Bring this to your HRT consult — the 9 questions

1. What symptom is this meant to treat?
2. Is it systemic (whole-body) or local (vaginal)?
3. Which hormone or hormones does it contain?
4. If I have a uterus, what endometrial-protection plan do I need?
5. Is it continuous (daily) or cyclic (part of the month)?
6. Is the exact product FDA-approved or compounded?
7. Why this route over the alternatives?
8. What side effects or bleeding changes should make me call you?
9. When and how will we check whether it’s working?

Quick questions about cost and coverage

• Is the visit covered, and is the exact medication on my plan’s formulary?
• Is prior authorization needed? Is a generic available?
• Are follow-ups, labs, and medication billed separately?

Quick questions about online care

• Who actually prescribes, and where are they licensed?
• How are safety concerns escalated?
• Can my prescription go to a local pharmacy?
• What happens if online care turns out not to be appropriate for me?

How did The HRT Index verify this guide?

This guide follows The HRT Index Verification Standard — our documented process: read the primary sources, keep FDA-approved and compounded options strictly separate, note what we couldn’t confirm, and re-check on a fixed schedule. We weigh our work against five pillars, in order: clinical legitimacy, care quality, medication fit, price transparency, and access.

We think you deserve to know how a health page was built before you trust it. So here’s ours.

Our source order: current FDA pages, prescribing information, and Drugs@FDA first; then ACOG and The Menopause Society; then peer-reviewed research; then official product labels; then provider sites for commercial facts only; and forums only for the language women use — never as medical evidence.

What’s fact vs. our judgment: the medical and regulatory claims here come from the primary sources named throughout. The framework — the five-decision map, the situation table, the order of questions — is our editorial work, and we label it that way.

Our update schedule:we re-check the fast-moving pieces (FDA wording, product availability, guidance changes) on a fixed cadence and update the “Last verified” date only when we’ve actually re-confirmed the facts. For provider data on our comparison pages, we re-verify top providers monthly and the full roster quarterly.

On money: as of June 2026, this page contains no provider-specific affiliate links. Find My HRT Path may connect you with providers The HRT Index has affiliate relationships with; that compensation never determines our rankings, which follow The HRT Index Verification Standard.

Frequently asked questions about the types of HRT

Still deciding?

Still not sure which HRT program is right for you? Take our free 60-second matching quiz.

Educational only. This tool does not diagnose, prescribe, or replace a licensed clinician.

Sources

• U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026.
• U.S. Food and Drug Administration. Menopausal Hormone Therapies with Updated Prescribing Information. Updated February 12, 2026.
• U.S. Food and Drug Administration. FDA Requests Labeling Changes… to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies. November 10, 2025.
• U.S. Department of Health and Human Services. Fact Sheet: FDA Initiates Removal of “Black Box” Warnings from Menopausal Hormone Replacement Therapy Products. November 10, 2025.
• U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
• U.S. Food and Drug Administration. Menopause (consumer information, incl. estriol).
• The Menopause Society. Hormone Therapy (patient education); statement on the FDA hormone therapy announcement, November 2025.
• American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy (Clinical Consensus No. 6, 2023); Hormone Therapy for Menopause (FAQ).
• Parish SJ, Simon JA, Davis SR, et al. ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021; and the Global Position Statement on testosterone therapy for women.
• 21 CFR § 1308.13 (testosterone as a Schedule III controlled substance).
• DailyMed product labels (Prometrium, Bijuva, Estring, Femring, and others) for product-specific details.
• Mayo Clinic and Cleveland Clinic patient references for delivery forms and bioidentical/compounded background.